Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL195776 | 0.97 | ALDH1A1 (0.43) | ALDH1A1PKMGSRRNPEPCPB2 | |
| SCHEMBL6794551 | 0.95 | ALDH1A1 (0.42) | ALDH1A1PKMGSRRNPEPCPB2 | |
| SCHEMBL28490356 | 0.93 | ALDH1A1 (0.49) | ALDH1A1PKMGSRRNPEPCPB2 | |
| SCHEMBL1696971 | 0.93 | ALDH1A1 (0.49) | ALDH1A1PKMGSRRNPEPCPB2 | |
| SCHEMBL1437767 | 0.88 | ALDH1A1 (0.50) | ALDH1A1PKMGSRRNPEPCPB2 | |
| SCHEMBL1696968 | 0.87 | GSR (0.44) | ALDH1A1PKMGSRRNPEPCPB2 | |
| SCHEMBL1696991 | 0.84 | ALDH1A1 (0.41) | ALDH1A1PKMGSRRNPEPCPB2 | |
| SCHEMBL1696978 | 0.83 | ALDH1A1 (0.40) | ALDH1A1PKMGSRRNPEPCPB2 | |
| SCHEMBL10409212 | 0.79 | KMT2A (0.50) | ALDH1A1PKMLMNACA12CA1 | |
| Lysine SCHEMBL5606291 | 0.78 | GSR (0.48) | ALDH1A1PKMGSRCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017064718-A1 | METHODS AND KITS FOR DETERMINING DEACYLASE ACTIVITY | The National Institute for Biotechnology in the Negev Ltd. (IL) | 2017-04-20 | — | — | WO | claimed |
| US-11110107-B2 | Methods for treatment of cancer by targeting SIRT5 | CORNELL UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20190298747-A1 | METHODS FOR TREATMENT OF CANCER BY TARGETING SIRT5 | CORNELL UNIVERSITY (US) | 2019-10-03 | — | — | US | disclosed |
| US-10342814-B2 | Methods for treatment of cancer by targeting Sirt5 | CORNELL UNIVERSITY (US) | 2019-07-09 | — | — | US | disclosed |
| CN-105037278-B | Sirt5 regulator and its screening technique | 康奈尔大学 | 2019-05-03 | — | — | CN | disclosed |
| EP-2596122-B1 | MODULATORS FOR SIRT5 AND ASSAYS FOR SCREENING SAME | UNIV CORNELL (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9932621-B2 | Modulators for Sirt5 and assays for screening same | CORNELL UNIVERSITY (US) | 2018-04-03 | — | — | US | disclosed |
| CN-105037278-A | Modulators for Sirt5 and assays for screening same | UNIV CORNELL | 2015-11-11 | — | — | CN | disclosed |
| CN-103097545-B | Sirt5 modulators and screening methods thereof | UNIV CORNELL | 2015-07-22 | — | — | CN | disclosed |
| US-20150057236-A1 | MODULATORS FOR SIRT5 AND ASSAYS FOR SCREENING SAME | CORNELL UNIVERSITY (US) | 2015-02-26 | — | — | US | disclosed |
| US-20140213530-A1 | METHODS FOR TREATMENT OF CANCER BY TARGETING SIRT5 | CORNELL UNIVERSITY (US) | 2014-07-31 | — | — | US | disclosed |
| EP-2596122-A2 | MODULATORS FOR SIRT5 AND ASSAYS FOR SCREENING SAME | Cornell University (US) | 2013-05-29 | — | — | EP | disclosed |
| CN-103097545-A | Sirt5 modulators and screening methods thereof | UNIV CORNELL | 2013-05-08 | — | — | CN | disclosed |
| WO-2013036720-A1 | METHODS FOR TREATMENT OF CANCER BY TARGETING SIRT5 | CORNELL UNIVERSITY (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2012006391-A2 | MODULATORS FOR SIRT5 AND ASSAYS FOR SCREENING SAME | CORNELL UNIVERSITY (US) | 2012-01-12 | — | — | WO | disclosed |
| EP-0248057-B1 | GLUCOSE TOLERANCE FACTOR AND METHOD OF MAKING SAME | ANHEUSER-BUSCH COMPANIES, INC. (US) | 1992-05-20 | — | — | EP | disclosed |
| US-4985439-A | REDUCES BLOOD SUGAR IN MAMMALS AND IS DERIVED FROM YEAST | ANHEUSER-BUSCH COMPANIES, INC. (US) | 1991-01-15 | — | — | US | disclosed |
| EP-0248057-A4 | GLUCOSE TOLERANCE FACTOR AND METHOD OF MAKING SAME. | ANHEUSER BUSCH (US) | 1988-06-23 | — | — | EP | disclosed |
| EP-0248057-A1 | GLUCOSE TOLERANCE FACTOR AND METHOD OF MAKING SAME. | ANHEUSER BUSCH (US) | 1987-12-09 | — | — | EP | disclosed |
| WO-1987003200-A1 | GLUCOSE TOLERANCE FACTOR AND METHOD OF MAKING SAME | ANHEUSER-BUSCH COMPANIES, INC. (US) | 1987-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213530-A1 | METHODS FOR TREATMENT OF CANCER BY TARGETING SIRT5 | SIRT2, SIRT1, SIRT3 | ALDH1A1 1493/4885PKM 2471/4885GSR 682/4885 |
| US-11110107-B2 | Methods for treatment of cancer by targeting SIRT5 | SIRT2, SIRT1, SIRT3 | ALDH1A1 1493/4885PKM 2471/4885GSR 682/4885 |
| US-20150057236-A1 | MODULATORS FOR SIRT5 AND ASSAYS FOR SCREENING SAME | SIRT5, SIRT6, SIRT1 | ALDH1A1 2504/4885PKM 1524/4885GSR 239/4885 |
| US-20190298747-A1 | METHODS FOR TREATMENT OF CANCER BY TARGETING SIRT5 | SIRT2, SIRT1, SIRT3 | ALDH1A1 1493/4885PKM 2471/4885GSR 682/4885 |
| US-10342814-B2 | Methods for treatment of cancer by targeting Sirt5 | SIRT2, SIRT1, SIRT3 | ALDH1A1 1493/4885PKM 2471/4885GSR 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.